INVO Fertility Receives Nasdaq Compliance Notice for Late Filings
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Source: seekingalpha
- Compliance Notice: INVO Fertility received a notice from Nasdaq indicating non-compliance with listing requirements due to late filings of financial reports, specifically the annual report for the year ended December 31, 2025, and the quarterly report for the quarter ended March 31, 2026.
- Impact of Delayed Reports: Despite the notice, INVO stated that it has no immediate effect on the listing or trading of its common stock on Nasdaq, reflecting the company's stability in the face of compliance issues.
- Remedial Actions: INVO filed its delayed annual report on June 2 and is working to complete and file the quarterly report as soon as possible, demonstrating the company's proactive approach to resolving compliance matters.
- Compliance Plan Timeline: Under Nasdaq rules, INVO must submit a compliance plan by June 22, 2026, and if accepted, Nasdaq may grant the company until October 13, 2026, to regain compliance, highlighting the urgency of the company's compliance efforts.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy IVF?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on IVF
About IVF
INVO Fertility Inc., formerly NAYA Biosciences, Inc., is a healthcare services company focused on the fertility marketplace and expanding access to assisted reproductive technology (ART) care for patients in need. Its segments include Fertility Clinic Services, INVOcell Device, and Therapeutics. It focuses on operating fertility clinics, including INVO Centers dedicated primarily to offering the intravaginal culture (IVC) procedure enabled by its INVOcell medical device (INVOcell) and United States-based, in vitro fertilization (IVF) clinics. It has two operational INVO Centers in the United States and one IVF clinic. It is also engaged in the sale and distribution of its INVOcell technology solution to third party-owned and operated fertility clinics. The INVOcell is a proprietary medical device that allows fertilization and early embryo development to take place in vivo within the woman's body. The IVC procedure provides patients with a natural, intimate, and affordable experience.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
INVO Fertility Reports FY2025 Financial Highlights and Strategic Developments
- Financial Performance Improvement: INVO Fertility reported FY2025 revenue of $6.84 million, a 5% increase from $6.53 million, indicating stable growth potential in the fertility healthcare market while solidifying its market position.
- Acquisition Expansion: The company successfully acquired Family Beginnings in Indiana in February 2026, adding a fourth operational fertility clinic expected to generate approximately $1.2 million in annual revenue, further enhancing its market presence in the Midwest.
- Financing and Capital Structure Optimization: Financing transactions totaling $11.5 million in December 2025 and January 2026 improved the company's financial flexibility, supporting its growth strategy and debt repayment, demonstrating significant improvement in its capital structure.
- Technological Innovation and Market Expansion: INVO Fertility issued a new patent for its INVOcell device and introduced time-lapse incubation technology at the Wisconsin Fertility Institute, enhancing clinical decision-making capabilities and reinforcing its innovative position in the fertility healthcare sector.
See More
INVO Fertility Receives Nasdaq Delinquency Notice
- Nasdaq Delinquency Notice: INVO Fertility received a delinquency notice from Nasdaq on May 27, 2026, for failing to timely file its 10-K and 10-Q reports, although this notice currently does not affect the trading of its stock.
- Reasons for Filing Delay: The delay in filing the 10-K was attributed to the need for additional time to review complex accounting matters, including tax provisions and derivative accounting, which may impact investor perceptions of the company's financial health.
- Compliance Plan Deadline: Under Nasdaq rules, the company must submit a compliance plan by June 22, 2026; if accepted, it will have 180 days (until October 13, 2026) to regain compliance, which is critical for maintaining its listing status.
- Growth Strategy: The company completed a $7.5 million financing and acquired Family Beginnings, an Indiana-based fertility clinic, in January 2026, which strengthened its operations and balance sheet, with the upcoming 10-Q expected to reflect positive progress from these strategic initiatives.
See More
INVO Fertility Receives Nasdaq Compliance Notice for Late Filings
- Compliance Notice: INVO Fertility received a notice from Nasdaq indicating non-compliance with listing requirements due to late filings of financial reports, specifically the annual report for the year ended December 31, 2025, and the quarterly report for the quarter ended March 31, 2026.
- Impact of Delayed Reports: Despite the notice, INVO stated that it has no immediate effect on the listing or trading of its common stock on Nasdaq, reflecting the company's stability in the face of compliance issues.
- Remedial Actions: INVO filed its delayed annual report on June 2 and is working to complete and file the quarterly report as soon as possible, demonstrating the company's proactive approach to resolving compliance matters.
- Compliance Plan Timeline: Under Nasdaq rules, INVO must submit a compliance plan by June 22, 2026, and if accepted, Nasdaq may grant the company until October 13, 2026, to regain compliance, highlighting the urgency of the company's compliance efforts.
See More
INVO BioScience Reports Narrowed Losses in FY Earnings
- Financial Performance: INVO BioScience reported a FY GAAP EPS of -$214.64, with total revenue of $6.84 million, indicating ongoing financial challenges despite some revenue generation.
- Clinic Revenue Growth: Consolidated clinic revenue increased by 4% to $6,721,057 compared to $6,450,431 last year, suggesting a slight recovery in market demand.
- Net Loss Improvement: The net loss from continuing operations was $5.3 million, an improvement from $7.7 million in the previous year, indicating progress in cost control measures.
- Adjusted EBITDA: The adjusted EBITDA stood at -$3.2 million, worsening from -$2.2 million year-over-year, highlighting ongoing challenges in restoring profitability.
See More
INVO Fertility Receives Nasdaq Compliance Notice
- Compliance Notice: INVO Fertility received a notice from Nasdaq indicating non-compliance with listing rules due to a delay in filing its annual report for the year ended December 31, 2025, although this notice does not have an immediate impact on its stock listing or trading.
- Remediation Plan: The company has 60 days to submit a plan to regain compliance and is currently working to complete the filing, citing the need for additional time to review complex accounting matters, which could affect its future financial transparency.
- Accounting Review: INVO Fertility noted that the complexity of accounting issues led to the delay in reporting, which may impact investor confidence in the company's financial health, potentially exerting downward pressure on its stock price.
- Market Reaction: While the current notice has not directly affected stock trading, investors should monitor whether the company can successfully submit its compliance plan within the stipulated timeframe to avoid further market uncertainty.
See More
INVO Fertility Announces 1-for-5 Reverse Stock Split
- Reverse Split Implementation: INVO Fertility announced a 1-for-5 reverse stock split effective March 27, 2026, which will reduce the outstanding shares from approximately 8,077,095 to about 1,615,419, thereby increasing the per-share price and enhancing market perception.
- Trading Symbol Unchanged: Post-split, the company's common stock will continue to trade under the same symbol 'IVF' on the Nasdaq Capital Market, which will help maintain investor recognition and market stability.
- Shareholder Rights Adjustment: All shareholders will have their holdings adjusted according to the reverse split ratio, with every 5 shares exchanged for 1 share, ensuring no loss of shareholder equity while providing cash compensation for fractional shares.
- Market Strategy Focus: INVO Fertility is dedicated to expanding assisted reproductive technology (ART) services, planning to enhance market share by establishing and operating more fertility clinics, and the reverse split will provide greater flexibility for future capital operations.
See More
INVO Fertility Reports FY2025 Financial Highlights and Strategic Developments
- Financial Performance Improvement: INVO Fertility reported FY2025 revenue of $6.84 million, a 5% increase from $6.53 million, indicating stable growth potential in the fertility healthcare market while solidifying its market position.
- Acquisition Expansion: The company successfully acquired Family Beginnings in Indiana in February 2026, adding a fourth operational fertility clinic expected to generate approximately $1.2 million in annual revenue, further enhancing its market presence in the Midwest.
- Financing and Capital Structure Optimization: Financing transactions totaling $11.5 million in December 2025 and January 2026 improved the company's financial flexibility, supporting its growth strategy and debt repayment, demonstrating significant improvement in its capital structure.
- Technological Innovation and Market Expansion: INVO Fertility issued a new patent for its INVOcell device and introduced time-lapse incubation technology at the Wisconsin Fertility Institute, enhancing clinical decision-making capabilities and reinforcing its innovative position in the fertility healthcare sector.
See More
INVO Fertility Receives Nasdaq Delinquency Notice
- Nasdaq Delinquency Notice: INVO Fertility received a delinquency notice from Nasdaq on May 27, 2026, for failing to timely file its 10-K and 10-Q reports, although this notice currently does not affect the trading of its stock.
- Reasons for Filing Delay: The delay in filing the 10-K was attributed to the need for additional time to review complex accounting matters, including tax provisions and derivative accounting, which may impact investor perceptions of the company's financial health.
- Compliance Plan Deadline: Under Nasdaq rules, the company must submit a compliance plan by June 22, 2026; if accepted, it will have 180 days (until October 13, 2026) to regain compliance, which is critical for maintaining its listing status.
- Growth Strategy: The company completed a $7.5 million financing and acquired Family Beginnings, an Indiana-based fertility clinic, in January 2026, which strengthened its operations and balance sheet, with the upcoming 10-Q expected to reflect positive progress from these strategic initiatives.
See More
INVO Fertility Receives Nasdaq Compliance Notice for Late Filings
- Compliance Notice: INVO Fertility received a notice from Nasdaq indicating non-compliance with listing requirements due to late filings of financial reports, specifically the annual report for the year ended December 31, 2025, and the quarterly report for the quarter ended March 31, 2026.
- Impact of Delayed Reports: Despite the notice, INVO stated that it has no immediate effect on the listing or trading of its common stock on Nasdaq, reflecting the company's stability in the face of compliance issues.
- Remedial Actions: INVO filed its delayed annual report on June 2 and is working to complete and file the quarterly report as soon as possible, demonstrating the company's proactive approach to resolving compliance matters.
- Compliance Plan Timeline: Under Nasdaq rules, INVO must submit a compliance plan by June 22, 2026, and if accepted, Nasdaq may grant the company until October 13, 2026, to regain compliance, highlighting the urgency of the company's compliance efforts.
See More
INVO BioScience Reports Narrowed Losses in FY Earnings
- Financial Performance: INVO BioScience reported a FY GAAP EPS of -$214.64, with total revenue of $6.84 million, indicating ongoing financial challenges despite some revenue generation.
- Clinic Revenue Growth: Consolidated clinic revenue increased by 4% to $6,721,057 compared to $6,450,431 last year, suggesting a slight recovery in market demand.
- Net Loss Improvement: The net loss from continuing operations was $5.3 million, an improvement from $7.7 million in the previous year, indicating progress in cost control measures.
- Adjusted EBITDA: The adjusted EBITDA stood at -$3.2 million, worsening from -$2.2 million year-over-year, highlighting ongoing challenges in restoring profitability.
See More
INVO Fertility Receives Nasdaq Compliance Notice
- Compliance Notice: INVO Fertility received a notice from Nasdaq indicating non-compliance with listing rules due to a delay in filing its annual report for the year ended December 31, 2025, although this notice does not have an immediate impact on its stock listing or trading.
- Remediation Plan: The company has 60 days to submit a plan to regain compliance and is currently working to complete the filing, citing the need for additional time to review complex accounting matters, which could affect its future financial transparency.
- Accounting Review: INVO Fertility noted that the complexity of accounting issues led to the delay in reporting, which may impact investor confidence in the company's financial health, potentially exerting downward pressure on its stock price.
- Market Reaction: While the current notice has not directly affected stock trading, investors should monitor whether the company can successfully submit its compliance plan within the stipulated timeframe to avoid further market uncertainty.
See More
INVO Fertility Announces 1-for-5 Reverse Stock Split
- Reverse Split Implementation: INVO Fertility announced a 1-for-5 reverse stock split effective March 27, 2026, which will reduce the outstanding shares from approximately 8,077,095 to about 1,615,419, thereby increasing the per-share price and enhancing market perception.
- Trading Symbol Unchanged: Post-split, the company's common stock will continue to trade under the same symbol 'IVF' on the Nasdaq Capital Market, which will help maintain investor recognition and market stability.
- Shareholder Rights Adjustment: All shareholders will have their holdings adjusted according to the reverse split ratio, with every 5 shares exchanged for 1 share, ensuring no loss of shareholder equity while providing cash compensation for fractional shares.
- Market Strategy Focus: INVO Fertility is dedicated to expanding assisted reproductive technology (ART) services, planning to enhance market share by establishing and operating more fertility clinics, and the reverse split will provide greater flexibility for future capital operations.
See More
